FDA Rationale for Breakpoints Recognition Decision: Minocycline for Stenotrophomonas maltophilia

Synopsis

The FDA has not previously recognized any minocycline breakpoints for S. maltophilia. Current CLSI Minocycline Breakpoints against S. maltophilia

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.